Methods for treating muscular dystrophy
First Claim
1. A method of decreasing muscle damage, increasing muscle repair, and/or increasing muscle function in a subject with a muscular dystrophy comprising administering systemically 100-1000 μ
- g of Galectin-1, Galectin-3 or a combination thereof to the subject, thereby improving muscle function, decreasing muscle damage and/or increasing muscle repair in the subject with the muscular dystrophy.
4 Assignments
0 Petitions
Accused Products
Abstract
Disclosed herein are methods for diagnosing, prognosing and treating muscular dystrophy. The disclosed methods can be used to diagnosis, prognosis or treat a subject with merosin-deficient congenital muscular dystrophy Type 1A (MDC1A), limb-girdle muscular dystrophy (LGMD), facioscapulohumeral (FHMD), Beckers muscular dystrophy (BMD) or Duchenne muscular dystrophy (DMD). Also disclosed are methods of determining the effectiveness of an agent for the treatment of muscular dystrophy. In an example, a method of diagnosing or prognosing a subject with muscular dystrophy includes detecting expression of Galectin-1 or Galectin-3 in a sample obtained from the subject at risk of having or having one or more signs or symptoms associated with muscular dystrophy, thereby diagnosing or prognosing the subject with muscular dystrophy. Also provided are methods of enhancing muscle regeneration, repair, or maintenance in a subject by administering galectin, such as Galectin-1 and/or Galectin-3 to a subject in need thereof.
-
Citations
17 Claims
-
1. A method of decreasing muscle damage, increasing muscle repair, and/or increasing muscle function in a subject with a muscular dystrophy comprising administering systemically 100-1000 μ
- g of Galectin-1, Galectin-3 or a combination thereof to the subject, thereby improving muscle function, decreasing muscle damage and/or increasing muscle repair in the subject with the muscular dystrophy.
- View Dependent Claims (2, 3, 4, 5)
- 6. A method of decreasing muscle damage, increasing muscle repair, and/or increasing muscle function in a subject with a muscular dystrophy comprising administering systemically at least 1 mg of Galectin-1, Galectin-3 or a combination thereof to the subject, thereby improving muscle function, decreasing muscle damage and/or increasing muscle repair in the subject with the muscular dystrophy.
- 10. A method of decreasing muscle damage, increasing muscle repair, and/or increasing muscle function in a subject with a muscular dystrophy comprising administering systemically a therapeutically effective amount of recombinant Galectin-1 protein, Galectin-3 protein or a combination thereof to the subject with muscular dystrophy thereby decreasing muscle damage, increasing muscle repair, and/or increasing muscle function in the subject with a muscular dystrophy.
Specification